Bellicum Pharmaceuticals (BLCM) PT Raised to $27 at Citi

Citi raised its price target on Bellicum Pharmaceuticals (NASDAQ: BLCM) to $27.00 (from $24.00) while maintaining a Buy rating.

Analyst Robyn Karnauskas comments "We think CAR-T tech value is not currently in the stock, as potential partners according to the company want to see data showing that the activation switch works first. Potential partners could be cell therapy cos looking to add switch technology or I/O cos that haven’t entered cell therapy yet. BLCM stresses that it is an integrated cell therapy co and wants to develop products w/ partners rather than just provide tech."

You May Also Be Interested In

• Snowflake Inc. (SNOW) PT Raised to $450 at Freedom Broker
• Zscaler (ZS) PT Raised to $225 at Stephens
• Clearway Energy Inc. (CWEN) PT Lowered to $38 at Jefferies